Santhera Pharmaceuticals Holding AG
SPHDF
Price:
$13.35
Market Cap:
$159.13M
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (...[Read more]
Industry
Biotechnology
IPO Date
2014-04-17
Stock Exchange
OTC
Ticker
SPHDF
PE Ratio
[-1.99]
ROE
[-521.53%]
Current Ratio
[1.02]
Dividend Yield
[0%]
Enterprise Value
[217.04M]
Dividend History
The ROE as of December 2025 (TTM) for Santhera Pharmaceuticals Holding AG (SPHDF) is -521.53%
According to Santhera Pharmaceuticals Holding AG’s latest financial reports and current stock price. The company's current ROE is -521.53%. This represents a change of -237.50% compared to the average of 379.31% of the last 4 quarters.
Santhera Pharmaceuticals Holding AG (SPHDF) Historical ROE (quarterly & annually)
How has SPHDF ROE performed in the past?
The mean historical ROE of Santhera Pharmaceuticals Holding AG over the last ten years is -349.96%. The current -521.53% ROE has changed 49.02% with respect to the historical average. Over the past ten years (40 quarters), SPHDF's ROE was at its highest in in the June 2025 quarter at 1.52%. The ROE was at its lowest in in the June 2020 quarter at -15155.71%.
Average
-349.96%
Median
-68.46%
Minimum
-4181.17%
Maximum
1.06%
Santhera Pharmaceuticals Holding AG (SPHDF) ROE by Quarter and Year
Discovering the peaks and valleys of Santhera Pharmaceuticals Holding AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 235.40%
Maximum Annual ROE = 1.06%
Minimum Annual Increase = -1292.45%
Minimum Annual ROE = -4181.17%
| Year | ROE | Change |
|---|---|---|
| 2024 | -151.54% | -265.82% |
| 2023 | 91.39% | -43.83% |
| 2022 | 162.70% | -103.89% |
| 2021 | -4181.17% | -492.66% |
| 2020 | 1.06% | -1292.45% |
| 2019 | -89.30% | -54.14% |
| 2018 | -194.71% | 21.88% |
| 2017 | -159.76% | 235.40% |
| 2016 | -47.63% | -950.69% |
| 2015 | 5.60% | -112.81% |
Santhera Pharmaceuticals Holding AG (SPHDF) Average ROE
How has SPHDF ROE performed in the past?
The current ROE of Santhera Pharmaceuticals Holding AG (SPHDF) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
34.18%
5-year avg
-602.76%
10-year avg
-349.96%
Santhera Pharmaceuticals Holding AG (SPHDF) ROE vs. Peers
How is SPHDF’s ROE compared to its peers?
Santhera Pharmaceuticals Holding AG’s ROE is greater than Genfit S.A. (-63.70%), greater than JW (Cayman) Therapeutics Co. Ltd (-59.45%), greater than Silence Therapeutics plc (-85.88%), greater than Molecular Partners AG (-50.31%), greater than Brii Biosciences Limited (-14.61%), greater than Botanix Pharmaceuticals Limited (-99.43%), greater than Innate Pharma S.A. (-658.91%), greater than NDT Pharmaceuticals Inc. (-20.34%), less than Oryzon Genomics S.A. (-4.20%), greater than NervGen Pharma Corp. (-879.68%),
| Company | ROE | Market cap |
|---|---|---|
| -63.70% | $206.16M | |
| -59.45% | $150.63M | |
| -85.88% | $255.06M | |
| -50.31% | $134.64M | |
| -14.61% | $173.42M | |
| -99.43% | $150.41M | |
| -658.91% | $183.43M | |
| -20.34% | $158.40M | |
| -4.20% | $264.95M | |
| -879.68% | $329.05M |
Build a custom stock screener for Santhera Pharmaceuticals Holding AG (SPHDF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Santhera Pharmaceuticals Holding AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Santhera Pharmaceuticals Holding AG (SPHDF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Santhera Pharmaceuticals Holding AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Santhera Pharmaceuticals Holding AG's ROE?
How is the ROE calculated for Santhera Pharmaceuticals Holding AG (SPHDF)?
What is the highest ROE for Santhera Pharmaceuticals Holding AG (SPHDF)?
What is the 3-year average ROE for Santhera Pharmaceuticals Holding AG (SPHDF)?
What is the 5-year average ROE for Santhera Pharmaceuticals Holding AG (SPHDF)?
How does the current ROE for Santhera Pharmaceuticals Holding AG (SPHDF) compare to its historical average?